These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18322301)

  • 1. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
    Colombo-Benkmann M; Li Z; Riemann B; Hengst K; Herbst H; Keuser R; Gross U; Rondot S; Raue F; Senninger N; Pützer BM; Frank-Raue K
    Eur J Endocrinol; 2008 Jun; 158(6):811-6. PubMed ID: 18322301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
    Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
    Frank-Raue K; Buhr H; Dralle H; Klar E; Senninger N; Weber T; Rondot S; Höppner W; Raue F
    Eur J Endocrinol; 2006 Aug; 155(2):229-36. PubMed ID: 16868135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
    Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
    Colombo C; Minna E; Rizzetti MG; Romeo P; Lecis D; Persani L; Mondellini P; Pierotti MA; Greco A; Fugazzola L; Borrello MG
    Orphanet J Rare Dis; 2015 Mar; 10():25. PubMed ID: 25887804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
    Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
    Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
    Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
    J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.
    Muzza M; Cordella D; Bombled J; Bressac-de Paillerets B; Guizzardi F; Francis Z; Beck-Peccoz P; Schlumberger M; Persani L; Fugazzola L
    Eur J Endocrinol; 2010 Apr; 162(4):771-7. PubMed ID: 20103606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
    Machens A; Lorenz K; Dralle H
    Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.
    Frank-Raue K; Machens A; Scheuba C; Niederle B; Dralle H; Raue F;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):259-63. PubMed ID: 18248648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?
    Baumgartner-Parzer SM; Lang R; Wagner L; Heinze G; Niederle B; Kaserer K; Waldhäusl W; Vierhapper H
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6232-6. PubMed ID: 16118333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.